528 results on '"Idh mutation"'
Search Results
2. Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1.
- Author
-
Wu, Xingkang, Li, Yang, Han, Chenchen, Li, Shifei, and Qin, Xuemei
- Subjects
- *
CANCER cell growth , *ISOCITRATE dehydrogenase , *TREATMENT effectiveness , *ANTINEOPLASTIC agents , *ADJUVANT chemotherapy , *GLUTAMINE - Abstract
Intrahepatic cholangiocarcinoma (ICC) is a universally lethal malignancy with increasing incidence. However, ICC patients receive limited benefits from current drugs; therefore, we must urgently explore new drugs for treating ICC. Quinolizidine alkaloids, as essential active ingredients extracted from Sophora alopecuroides Linn, can suppress cancer cell growth via numerous mechanisms and have therapeutic effects on liver-related diseases. However, the impact of quinolizidine alkaloids on intrahepatic cholangiocarcinoma has not been fully studied. In this article, the in vitro anti-ICC activities of six natural quinolizidine alkaloids were explored. Aloperine was the most potent antitumor compound among the tested quinolizidine alkaloids, and it preferentially inhibited RBE cells rather than HCCC-9810 cells. Mechanistically, aloperine can potentially decrease glutamate content by inhibiting the hydrolysis of glutamine, reducing D-2-hydroxyglutarate levels and, consequently, leading to preferential growth inhibition in isocitrate dehydrogenase (IDH)-mutant ICC cells. In addition, aloperine preferentially resensitizes RBE cells to 5-fluorouracil, AGI-5198 and olaparib. This article demonstrates that aloperine shows preferential antitumor effects in intrahepatic cholangiocarcinoma cells harboring the mutant IDH1 by decreasing D-2-hydroxyglutarate, suggesting that aloperine could be used as a lead compound or adjuvant chemotherapy drug to treat ICC harboring the mutant IDH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
- Author
-
Incyte Corporation, University of Pennsylvania, and Stephen Bagley, MD, MSCE, Assistant Professor of Medicine
- Published
- 2023
4. Extracranial metastatic oligodendroglioma with molecular progression, case presentation
- Author
-
Nour Kurdi, Attila Mokánszki, Ingrid Balogh, Anikó Ujfalusi, Sándor Szabó, Gábor Méhes, and Judit Bedekovics
- Subjects
Oligodendroglioma ,Extraaxial metastasis ,IDH mutation ,Bone marrow ,Molecular progression ,Pathology ,RB1-214 - Abstract
Abstract Background Extraneural metastasis of central nervous system tumors is generally rare and most often reported in glioblastomas and medulloblastomas, whereas oligodendrogliomas seem to have the lowest risk of extracranial metastasis. Given its infrequent occurrence, both the diagnosis and therapy of metastatic oligodendroglioma is often challenging. Case presentation This case study presents an oligodendroglioma, the isocitrate dehydrogenase 1 (IDH1) mutant, 1p/19q-codeleted tumor with bone marrow metastasis. The significance of this case lies in the comprehensive molecular analysis conducted for both the primary tumor and the metastasis. Chromosome 7 trisomy and chromosome 10 monosomy (+ 7/-10) were detected in the metastasis indicating molecular progression, which, to the best of our knowledge, has not been previously documented in metastatic oligodendroglioma. Conclusions This case study serves additional information for better understanding of the metastatic capabilities of CNS tumors.
- Published
- 2024
- Full Text
- View/download PDF
5. Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors
- Author
-
Malgorzata Perycz, Michal J. Dabrowski, Marta Jardanowska-Kotuniak, Adria-Jaume Roura, Bartlomiej Gielniewski, Karolina Stepniak, Michał Dramiński, Iwona A. Ciechomska, Bozena Kaminska, and Bartosz Wojtas
- Subjects
Differentiation ,Glioblastoma ,IDH mutation ,REST ,KAISO ,ZBTB33 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract The RE1-silencing transcription factor (REST) acts either as a repressor or activator of transcription depending on the genomic and cellular context. REST is a key player in brain cell differentiation by inducing chromatin modifications, including DNA methylation, in a proximity of its binding sites. Its dysfunction may contribute to oncogenesis. Mutations in IDH1/2 significantly change the epigenome contributing to blockade of cell differentiation and glioma development. We aimed at defining how REST modulates gene activation and repression in the context of the IDH mutation-related phenotype in gliomas. We studied the effects of REST knockdown, genome wide occurrence of REST binding sites, and DNA methylation of REST motifs in IDH wild type and IDH mutant gliomas. We found that REST target genes, REST binding patterns, and TF motif occurrence proximal to REST binding sites differed in IDH wild-type and mutant gliomas. Among differentially expressed REST targets were genes involved in glial cell differentiation and extracellular matrix organization, some of which were differentially methylated at promoters or gene bodies. REST knockdown differently impacted invasion of the parental or IDH1 mutant glioma cells. The canonical REST-repressed gene targets showed significant correlation with the GBM NPC-like cellular state. Interestingly, results of REST or KAISO silencing suggested the interplay between these TFs in regulation of REST-activated and repressed targets. The identified gene regulatory networks and putative REST cooperativity with other TFs, such as KAISO, show distinct REST target regulatory networks in IDH-WT and IDH-MUT gliomas, without concomitant DNA methylation changes. We conclude that REST could be an important therapeutic target in gliomas.
- Published
- 2024
- Full Text
- View/download PDF
6. Extracranial metastatic oligodendroglioma with molecular progression, case presentation.
- Author
-
Kurdi, Nour, Mokánszki, Attila, Balogh, Ingrid, Ujfalusi, Anikó, Szabó, Sándor, Méhes, Gábor, and Bedekovics, Judit
- Subjects
- *
ISOCITRATE dehydrogenase , *METASTASIS , *BONE marrow ,CENTRAL nervous system tumors ,BONE marrow cancer - Abstract
Background: Extraneural metastasis of central nervous system tumors is generally rare and most often reported in glioblastomas and medulloblastomas, whereas oligodendrogliomas seem to have the lowest risk of extracranial metastasis. Given its infrequent occurrence, both the diagnosis and therapy of metastatic oligodendroglioma is often challenging. Case presentation: This case study presents an oligodendroglioma, the isocitrate dehydrogenase 1 (IDH1) mutant, 1p/19q-codeleted tumor with bone marrow metastasis. The significance of this case lies in the comprehensive molecular analysis conducted for both the primary tumor and the metastasis. Chromosome 7 trisomy and chromosome 10 monosomy (+ 7/-10) were detected in the metastasis indicating molecular progression, which, to the best of our knowledge, has not been previously documented in metastatic oligodendroglioma. Conclusions: This case study serves additional information for better understanding of the metastatic capabilities of CNS tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors.
- Author
-
Perycz, Malgorzata, Dabrowski, Michal J., Jardanowska-Kotuniak, Marta, Roura, Adria-Jaume, Gielniewski, Bartlomiej, Stepniak, Karolina, Dramiński, Michał, Ciechomska, Iwona A., Kaminska, Bozena, and Wojtas, Bartosz
- Subjects
- *
TRANSCRIPTION factors , *EPIGENOMICS , *GENE regulatory networks , *GLIOMAS , *CELL lines , *GENE expression - Abstract
The RE1-silencing transcription factor (REST) acts either as a repressor or activator of transcription depending on the genomic and cellular context. REST is a key player in brain cell differentiation by inducing chromatin modifications, including DNA methylation, in a proximity of its binding sites. Its dysfunction may contribute to oncogenesis. Mutations in IDH1/2 significantly change the epigenome contributing to blockade of cell differentiation and glioma development. We aimed at defining how REST modulates gene activation and repression in the context of the IDH mutation-related phenotype in gliomas. We studied the effects of REST knockdown, genome wide occurrence of REST binding sites, and DNA methylation of REST motifs in IDH wild type and IDH mutant gliomas. We found that REST target genes, REST binding patterns, and TF motif occurrence proximal to REST binding sites differed in IDH wild-type and mutant gliomas. Among differentially expressed REST targets were genes involved in glial cell differentiation and extracellular matrix organization, some of which were differentially methylated at promoters or gene bodies. REST knockdown differently impacted invasion of the parental or IDH1 mutant glioma cells. The canonical REST-repressed gene targets showed significant correlation with the GBM NPC-like cellular state. Interestingly, results of REST or KAISO silencing suggested the interplay between these TFs in regulation of REST-activated and repressed targets. The identified gene regulatory networks and putative REST cooperativity with other TFs, such as KAISO, show distinct REST target regulatory networks in IDH-WT and IDH-MUT gliomas, without concomitant DNA methylation changes. We conclude that REST could be an important therapeutic target in gliomas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas
- Author
-
Bredel, Markus, Espinosa, Lluís, Kim, Hyunsoo, Scholtens, Denise M, McElroy, Joseph P, Rajbhandari, Rajani, Meng, Wei, Kollmeyer, Thomas M, Malta, Tathiane M, Quezada, Michael A, Harsh, Griffith R, Lobo-Jarne, Teresa, Solé, Laura, Merati, Aran, Nagaraja, Surya, Nair, Sindhu, White, Jaclyn J, Thudi, Nanda K, Fleming, Jessica L, Webb, Amy, Natsume, Atsushi, Ogawa, Seishi, Weber, Ruthild G, Bertran, Joan, Haque, S Jaharul, Hentschel, Bettina, Miller, C Ryan, Furnari, Frank B, Chan, Timothy A, Grosu, Anca-Ligia, Weller, Michael, Barnholtz-Sloan, Jill S, Monje, Michelle, Noushmehr, Houtan, Jenkins, Robert B, Rogers, C Leland, MacDonald, David R, Pugh, Stephanie L, and Chakravarti, Arnab
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Rare Diseases ,Orphan Drug ,Genetics ,Brain Disorders ,Brain Cancer ,Human Genome ,Child ,Humans ,Brain Neoplasms ,Epigenome ,Glioma ,Haploinsufficiency ,Mutation ,NF-KappaB Inhibitor alpha ,Isocitrate Dehydrogenase ,H3K27M mutation ,IDH mutation ,NFKBIA deletion ,glioma ,haploinsufficiency ,methylome ,nomogram ,tumor suppressor ,Biomedical and clinical sciences - Abstract
Genetic alterations help predict the clinical behavior of diffuse gliomas, but some variability remains uncorrelated. Here, we demonstrate that haploinsufficient deletions of chromatin-bound tumor suppressor NFKB inhibitor alpha (NFKBIA) display distinct patterns of occurrence in relation to other genetic markers and are disproportionately present at recurrence. NFKBIA haploinsufficiency is associated with unfavorable patient outcomes, independent of genetic and clinicopathologic predictors. NFKBIA deletions reshape the DNA and histone methylome antipodal to the IDH mutation and induce a transcriptome landscape partly reminiscent of H3K27M mutant pediatric gliomas. In IDH mutant gliomas, NFKBIA deletions are common in tumors with a clinical course similar to that of IDH wild-type tumors. An externally validated nomogram model for estimating individual patient survival in IDH mutant gliomas confirms that NFKBIA deletions predict comparatively brief survival. Thus, NFKBIA haploinsufficiency aligns with distinct epigenome changes, portends a poor prognosis, and should be incorporated into models predicting the disease fate of diffuse gliomas.
- Published
- 2023
9. Multi-omics reveals the impact of cancer-associated fibroblasts on the prognosis and treatment response of adult diffuse highest-grade gliomas
- Author
-
Ganghua Zhang, Panpan Tai, Jianing Fang, Zhanwang Wang, Rui Yu, Zhijing Yin, and Ke Cao
- Subjects
Adult diffuse highest-grade gliomas ,CAF ,Artificial neural network ,IDH mutation ,Immunotherapy ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Background: Cancer associated fibroblasts (CAF), an important cancer-promoting and immunosuppressive component of the tumor immune microenvironment (TIME), have recently been found to infiltrate adult diffuse highest-grade gliomas (ADHGG) (gliomas of grade IV). Methods: Gene expression and clinical data of ADHGG patients were obtained from the CGGA and TCGA databases. Consensus clustering was used to identify CAF subtypes based on CAF key genes acquired from single-cell omics and spatial transcriptomomics. CIBERSORT, ssGSEA, MCPcounter, and ESTIMATE analyses were used to assess the TIME of GBM. Survival analysis, drug sensitivity analysis, TCIA database, TIDE and cMap algorithms were used to compare the prognosis and treatment response between patients with different CAF subtypes. An artificial neural network (ANN) model based on random forest was constructed to exactly identify CAF subtypes, which was validated in a real-world patient cohort of ADHGG. Results: Consensus clustering classified ADHGG into two CAF subtypes. Compared with subtype B, patients with ADHGG subtype A had a poorer prognosis, worse responsiveness to immunotherapy and radiotherapy, higher CAF infiltration in TIME, but higher sensitivity to temozolomide. Furthermore, patients with subtype A had a much lower proportion of IDH mutations. Finally, the ANN model based on five genes (COL3A1, COL1A2, CD248, FN1, and COL1A1) could exactly discriminate CAF subtypes, and the validation of the real-world cohort indicated consistent results with the bioinformatics analyses. Conclusion: This study revealed a novel CAF subtype to distinguish ADHGG patients with different prognosis and treatment responsiveness, which may be helpful for accurate clinical decision-making of ADHGG.
- Published
- 2024
- Full Text
- View/download PDF
10. Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation
- Author
-
Saiko Kino, Masayuki Kanamori, Yoshiteru Shimoda, Kuniyasu Niizuma, Hidenori Endo, and Yuji Matsuura
- Subjects
Glioma ,IDH mutation ,Blood biomarkers ,Protein aggregation ,Amyloid ,Mid-infrared absorption spectroscopy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Glioma is a primary brain tumor and the assessment of its molecular profile in a minimally invasive manner is important in determining treatment strategies. Among the molecular abnormalities of gliomas, mutations in the isocitrate dehydrogenase (IDH) gene are strong predictors of treatment sensitivity and prognosis. In this study, we attempted to non-invasively diagnose glioma development and the presence of IDH mutations using multivariate analysis of the plasma mid-infrared absorption spectra for a comprehensive and sensitive view of changes in blood components associated with the disease and genetic mutations. These component changes are discussed in terms of absorption wavenumbers that contribute to differentiation. Methods Plasma samples were collected at our institutes from 84 patients with glioma (13 oligodendrogliomas, 17 IDH-mutant astrocytoma, 7 IDH wild-type diffuse glioma, and 47 glioblastomas) before treatment initiation and 72 healthy participants. FTIR-ATR spectra were obtained for each plasma sample, and PLS discriminant analysis was performed using the absorbance of each wavenumber in the fingerprint region of biomolecules as the explanatory variable. This data was used to distinguish patients with glioma from healthy participants and diagnose the presence of IDH mutations. Results The derived classification algorithm distinguished the patients with glioma from healthy participants with 83% accuracy (area under the curve (AUC) in receiver operating characteristic (ROC) = 0.908) and diagnosed the presence of IDH mutation with 75% accuracy (AUC = 0.752 in ROC) in cross-validation using 30% of the total test data. The characteristic changes in the absorption spectra suggest an increase in the ratio of β-sheet structures in the conformational composition of blood proteins of patients with glioma. Furthermore, these changes were more pronounced in patients with IDH-mutant gliomas. Conclusions The plasma infrared absorption spectra could be used to diagnose gliomas and the presence of IDH mutations in gliomas with a high degree of accuracy. The spectral shape of the protein absorption band showed that the ratio of β-sheet structures in blood proteins was significantly higher in patients with glioma than in healthy participants, and protein aggregation was a distinct feature in patients with glioma with IDH mutations.
- Published
- 2024
- Full Text
- View/download PDF
11. Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.
- Author
-
Kino, Saiko, Kanamori, Masayuki, Shimoda, Yoshiteru, Niizuma, Kuniyasu, Endo, Hidenori, and Matsuura, Yuji
- Subjects
- *
BRAIN tumors , *BLOOD plasma , *GLIOMAS , *BLOOD proteins , *ISOCITRATE dehydrogenase , *RECEIVER operating characteristic curves - Abstract
Background: Glioma is a primary brain tumor and the assessment of its molecular profile in a minimally invasive manner is important in determining treatment strategies. Among the molecular abnormalities of gliomas, mutations in the isocitrate dehydrogenase (IDH) gene are strong predictors of treatment sensitivity and prognosis. In this study, we attempted to non-invasively diagnose glioma development and the presence of IDH mutations using multivariate analysis of the plasma mid-infrared absorption spectra for a comprehensive and sensitive view of changes in blood components associated with the disease and genetic mutations. These component changes are discussed in terms of absorption wavenumbers that contribute to differentiation. Methods: Plasma samples were collected at our institutes from 84 patients with glioma (13 oligodendrogliomas, 17 IDH-mutant astrocytoma, 7 IDH wild-type diffuse glioma, and 47 glioblastomas) before treatment initiation and 72 healthy participants. FTIR-ATR spectra were obtained for each plasma sample, and PLS discriminant analysis was performed using the absorbance of each wavenumber in the fingerprint region of biomolecules as the explanatory variable. This data was used to distinguish patients with glioma from healthy participants and diagnose the presence of IDH mutations. Results: The derived classification algorithm distinguished the patients with glioma from healthy participants with 83% accuracy (area under the curve (AUC) in receiver operating characteristic (ROC) = 0.908) and diagnosed the presence of IDH mutation with 75% accuracy (AUC = 0.752 in ROC) in cross-validation using 30% of the total test data. The characteristic changes in the absorption spectra suggest an increase in the ratio of β-sheet structures in the conformational composition of blood proteins of patients with glioma. Furthermore, these changes were more pronounced in patients with IDH-mutant gliomas. Conclusions: The plasma infrared absorption spectra could be used to diagnose gliomas and the presence of IDH mutations in gliomas with a high degree of accuracy. The spectral shape of the protein absorption band showed that the ratio of β-sheet structures in blood proteins was significantly higher in patients with glioma than in healthy participants, and protein aggregation was a distinct feature in patients with glioma with IDH mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
- Published
- 2023
13. Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1
- Author
-
Xingkang Wu, Yang Li, Chenchen Han, Shifei Li, and Xuemei Qin
- Subjects
quinolizidine alkaloids ,aloperine ,intrahepatic cholangiocarcinoma ,D-2-hydroxyglutarate ,IDH mutation ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Intrahepatic cholangiocarcinoma (ICC) is a universally lethal malignancy with increasing incidence. However, ICC patients receive limited benefits from current drugs; therefore, we must urgently explore new drugs for treating ICC. Quinolizidine alkaloids, as essential active ingredients extracted from Sophora alopecuroides Linn, can suppress cancer cell growth via numerous mechanisms and have therapeutic effects on liver-related diseases. However, the impact of quinolizidine alkaloids on intrahepatic cholangiocarcinoma has not been fully studied. In this article, the in vitro anti-ICC activities of six natural quinolizidine alkaloids were explored. Aloperine was the most potent antitumor compound among the tested quinolizidine alkaloids, and it preferentially inhibited RBE cells rather than HCCC-9810 cells. Mechanistically, aloperine can potentially decrease glutamate content by inhibiting the hydrolysis of glutamine, reducing D-2-hydroxyglutarate levels and, consequently, leading to preferential growth inhibition in isocitrate dehydrogenase (IDH)-mutant ICC cells. In addition, aloperine preferentially resensitizes RBE cells to 5-fluorouracil, AGI-5198 and olaparib. This article demonstrates that aloperine shows preferential antitumor effects in intrahepatic cholangiocarcinoma cells harboring the mutant IDH1 by decreasing D-2-hydroxyglutarate, suggesting that aloperine could be used as a lead compound or adjuvant chemotherapy drug to treat ICC harboring the mutant IDH.
- Published
- 2024
- Full Text
- View/download PDF
14. Metabolic Characterization of Space Occupying Lesions of the Brain (FASTMRSI)
- Author
-
Swiss National Science Foundation
- Published
- 2023
15. Advances in molecular and imaging biomarkers in lower-grade gliomas.
- Author
-
Picca, Alberto, Bruno, Francesco, Nichelli, Lucia, Sanson, Marc, and Rudà, Roberta
- Abstract
Lower-grade (grade 2–3) gliomas (LGGs) constitutes a group of primary brain tumors with variable clinical behaviors and treatment responses. Recent advancements in molecular biology have redefined their classification, and novel imaging modalities emerged for the noninvasive diagnosis and follow-up. This review comprehensively analyses the current knowledge on molecular and imaging biomarkers in LGGs. Key molecular alterations, such as IDH mutations and 1p/19q codeletion, are discussed for their prognostic and predictive implications in guiding treatment decisions. Moreover, the authors explore theranostic biomarkers for the potential of tailored therapies. Additionally, they also describe the utility of advanced imaging modalities, including widely available techniques, as dynamic susceptibility contrast perfusion-weighted imaging and less validated, emerging approaches, for the noninvasive LGGs characterization and follow-up. The integration of molecular markers enhanced the stratification of LGGs, leading to the new concept of integrated histomolecular classification. While the IDH mutation is an established key prognostic and predictive marker, recent results from IDH inhibitors trials showed its potential value as a theranostic marker. In this setting, advanced MRI techniques such as 2-D-hydroxyglutarate spectroscopy are very promising for the noninvasive diagnosis and monitoring of LGGs. This progress offers exciting prospects for personalized medicine and improved treatment outcomes in LGGs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Investigating the value of radiomics stemming from DSC quantitative biomarkers in IDH mutation prediction in gliomas.
- Author
-
Ioannidis, Georgios S., Pigott, Laura Elin, Iv, Michael, Surlan-Popovic, Katarina, Wintermark, Max, Bisdas, Sotirios, and Marias, Kostas
- Subjects
RADIOMICS ,GLIOMAS ,BLOOD flow ,BIOMARKERS ,BRAIN tumors ,MATHEMATICAL models - Abstract
Objective: This study aims to assess the value of biomarker based radiomics to predict IDH mutation in gliomas. The patient cohort consists of 160 patients histopathologicaly proven of primary glioma (WHO grades 2-4) from 3 different centers. Methods: To quantify the DSC perfusion signal two different mathematical modeling methods were used (Gamma fitting, leakage correction algorithms) considering the assumptions about the compartments contributing in the blood flow between the extra- and intra vascular space. Results: The Mean slope of increase (MSI) and the K
1 parameter of the bidirectional exchange model exhibited the highest performance with (ACC 74.3% AUROC 74.2%) and (ACC 75% AUROC 70.5%) respectively. Conclusion: The proposed framework on DSC-MRI radiogenomics in gliomas has the potential of becoming a reliable diagnostic support tool exploiting the mathematical modeling of the DSC signal to characterize IDH mutation status through a more reproducible and standardized signal analysis scheme for facilitating clinical translation. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
17. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience
- Author
-
Elisabetta Setola, S. Benini, A. Righi, G. Gamberi, E. Carretta, C. Ferrari, S. Avnet, E. Palmerini, G. Magagnoli, M. Gambarotti, P. L. Lollini, M. Cesari, S. Cocchi, A. Paioli, A. Longhi, K. Scotlandi, M. A. Laginestra, D. M. Donati, N. Baldini, and T. Ibrahim
- Subjects
Chondrosarcoma ,IDH mutation ,Prognostic factors ,cancer metabolism ,Sarcoma ,Bone sarcoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Heterozygous isocitrate dehydrogenase (IDH) mutations occur in about half of conventional central bone chondrosarcomas (CCBC). Aim of this study was to assess the frequency and prognostic impact of IDH mutations in high grade CCBC patients. Methods 64 patients with G2 and G3 CCBC were included. DNA extraction, PCR amplification of IDH1/2 exon 4s, and sequencing analysis with Sanger were performed. Results IDH mutations were detected in 24/54 patients (44%): IDH1 in 18, IDH2 in 4, and both IDH1/2 in 2 patients. The frequency of mutations was 37% in G2 vs. 69% in G3 (p = 0.039), and 100% in three Ollier disease associated chondrosarcoma. 5-year overall survival (OS) at 124 months (range 1-166) was 51%, with no significant difference based on the IDH mutational status: 61% in IDHmut vs. 44% in IDH wild type (IDHwt). The 5-year relapse free survival (RFS) was 33% (95% CI:10–57) for IDHmut vs. 57% (95%CI: 30–77) for IDHwt. Progression free survival (PFS) was 25% (95%CI:1–65) IDHmut vs. 16% (95%CI: 0.7–52) IDHwt. 55% (5/9) of IDHmut G2 became higher grade at the recurrence, as compared with 25% (3/12) of G2 IDHwt. Conclusions This study shows a higher frequency of IDH mutations in G3 CCBC as compared with G2. No significant differences in OS, RFS, and PFS by mutational status were detected. After relapse, a higher rate of G3 for IDH mutated CCBC was observed.
- Published
- 2023
- Full Text
- View/download PDF
18. Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
- Author
-
Tatekawa, Hiroyuki, Hagiwara, Akifumi, Uetani, Hiroyuki, Bahri, Shadfar, Raymond, Catalina, Lai, Albert, Cloughesy, Timothy F, Nghiemphu, Phioanh L, Liau, Linda M, Pope, Whitney B, Salamon, Noriko, and Ellingson, Benjamin M
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Brain Disorders ,Biomedical Imaging ,Clinical Research ,Rare Diseases ,Neurosciences ,Machine Learning and Artificial Intelligence ,Brain Neoplasms ,Female ,Glioma ,Humans ,Isocitrate Dehydrogenase ,Machine Learning ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Positron-Emission Tomography ,Retrospective Studies ,Machine learning ,F-18-DOPA PET ,MRI ,IDH mutation ,Clustering ,Diffuse glioma ,18F-DOPA PET ,Nuclear Medicine & Medical Imaging ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundThe purpose of this study was to develop a voxel-wise clustering method of multiparametric magnetic resonance imaging (MRI) and 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) positron emission tomography (PET) images using an unsupervised, two-level clustering approach followed by support vector machine in order to classify the isocitrate dehydrogenase (IDH) status of gliomas.MethodsSixty-two treatment-naïve glioma patients who underwent FDOPA PET and MRI were retrospectively included. Contrast enhanced T1-weighted images, T2-weighted images, fluid-attenuated inversion recovery images, apparent diffusion coefficient maps, and relative cerebral blood volume maps, and FDOPA PET images were used for voxel-wise feature extraction. An unsupervised two-level clustering approach, including a self-organizing map followed by the K-means algorithm was used, and each class label was applied to the original images. The logarithmic ratio of labels in each class within tumor regions was applied to a support vector machine to differentiate IDH mutation status. The area under the curve (AUC) of receiver operating characteristic curves, accuracy, and F1-socore were calculated and used as metrics for performance.ResultsThe associations of multiparametric imaging values in each cluster were successfully visualized. Multiparametric images with 16-class clustering revealed the highest classification performance to differentiate IDH status with the AUC, accuracy, and F1-score of 0.81, 0.76, and 0.76, respectively.ConclusionsMachine learning using an unsupervised two-level clustering approach followed by a support vector machine classified the IDH mutation status of gliomas, and visualized voxel-wise features from multiparametric MRI and FDOPA PET images. Unsupervised clustered features may improve the understanding of prioritizing multiparametric imaging for classifying IDH status.
- Published
- 2021
19. Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm.
- Author
-
Askari, Pegah, Dimitrov, Ivan, Ganji, Sandeep, Tiwari, Vivek, Levy, Michael, Patel, Toral, Pan, Edward, Mickey, Bruce, Malloy, Craig, Maher, Elizabeth, and Choi, Changho
- Subjects
1H MRS ,2-Hydroxyglutarate ,2HG ,3T ,IDH mutation ,Lip ,TE 97 ms PRESS ,lipids ,Brain Neoplasms ,Glioma ,Glutarates ,Humans ,Lipids ,Magnetic Resonance Spectroscopy - Abstract
PURPOSE: 1 H MRS provides a noninvasive tool for identifying mutations in isocitrate dehydrogenase (IDH). Quantification of the prominent 2-hydroxyglutarate (2HG) resonance at 2.25 ppm is often confounded by the lipid resonance at the same frequency in tumors with elevated lipids. We propose a new spectral fitting approach to separate these overlapped signals, therefore, improving 2HG evaluation. METHODS: TE 97 ms PRESS was acquired at 3T from 42 glioma patients. New lipid basis sets were created, in which the small lipid 2.25-ppm signal strength was preset with reference to the lipid signal at 0.9 ppm, incorporating published fat relaxation data. LCModel fitting using the new lipid bases (Fitting method 2) was conducted along with fitting using the LCModel built-in lipid basis set (Fitting method 1), in which the lipid 2.25-ppm signal is assessed with reference to the lipid 1.3-ppm signal. In-house basis spectra of low-molecular-weight metabolites were used in both fitting methods. RESULTS: Fitting method 2 showed marked improvement in identifying IDH mutational status compared with Fitting method 1. 2HG estimates from Fitting method 2 were overall smaller than those from Fitting method 1, which was because of differential assignment of the signal at 2.25 ppm to lipids. In receiver operating characteristic analysis, Fitting method 2 provided a complete distinction between IDH mutation and wild-type whereas Fitting method 1 did not. CONCLUSION: The data suggest that 1 H MR spectral fitting using the new lipid basis set provides a robust fitting strategy that improves 2HG evaluation in brain tumors with elevated lipids.
- Published
- 2021
20. PTPRZ1-MET FUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial
- Author
-
Zhaoshi Bao, Shouwei Li, Liang Wang, Bisi Zhang, Peilong Zhang, Hepeng Shi, Xiaoguang Qiu, and Tao Jiang
- Subjects
Glioblastoma ,IDH mutation ,PTPRZ1-MET ,Vebreltinib ,Phase II/III ,Clinical trial ,Surgery ,RD1-811 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background PTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma, which was a target by a MET inhibitor vebreltinib. However, little is known about the further efficacy of vebreltinib among more glioma patients. This trial aims to evaluate the safety and efficacy of vebreltinib enteric-coated capsules in the treatment of sGBM/IDH mutant glioblastoma patients with the ZM fusion gene. Methods This multicentric, randomized, open-label, controlled trial plans to include 19 neurosurgical centers and recruit 84 sGBM or IDH mutant glioblastoma patients with the ZM fusion gene. This trial enrolls sGBM or IDH mutant glioblastoma patients with the inclusion criteria and without the exclusion criteria. It was registered with chinadrugtrials.org.cn (CTR20181664). The primary efficacy endpoint is overall survival (OS). The secondary endpoints are progression-free survival (PFS) and objective response rate (ORR). Discussion If proven effective, this targeted multifaceted intervention protocol will be extended for more glioma patients as a protocol to evaluate the safety and efficacy of MET inhibitors. Trial registration It was registered with chinadrugtrials.org.cn (CTR20181664).
- Published
- 2023
- Full Text
- View/download PDF
21. Vorasidenib in IDH1/2-mutant low-grade glioma: the grey zone of patient’s selection
- Author
-
Lidia Gatto, Vincenzo Di Nunno, Alicia Tosoni, Stefania Bartolini, Lucia Ranieri, and Enrico Franceschi
- Subjects
vorasidenib ,low grade glioma ,IDH 1/2 mutation ,IDH gliomas mut ,IDH mutation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2024
- Full Text
- View/download PDF
22. Investigating the value of radiomics stemming from DSC quantitative biomarkers in IDH mutation prediction in gliomas
- Author
-
Georgios S. Ioannidis, Laura Elin Pigott, Michael Iv, Katarina Surlan-Popovic, Max Wintermark, Sotirios Bisdas, and Kostas Marias
- Subjects
dynamic susceptibility contrast MRI ,gliomas ,radiogenomics ,IDH mutation ,generalizability ,explainability ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
ObjectiveThis study aims to assess the value of biomarker based radiomics to predict IDH mutation in gliomas. The patient cohort consists of 160 patients histopathologicaly proven of primary glioma (WHO grades 2–4) from 3 different centers.MethodsTo quantify the DSC perfusion signal two different mathematical modeling methods were used (Gamma fitting, leakage correction algorithms) considering the assumptions about the compartments contributing in the blood flow between the extra- and intra vascular space.ResultsThe Mean slope of increase (MSI) and the K1 parameter of the bidirectional exchange model exhibited the highest performance with (ACC 74.3% AUROC 74.2%) and (ACC 75% AUROC 70.5%) respectively.ConclusionThe proposed framework on DSC-MRI radiogenomics in gliomas has the potential of becoming a reliable diagnostic support tool exploiting the mathematical modeling of the DSC signal to characterize IDH mutation status through a more reproducible and standardized signal analysis scheme for facilitating clinical translation.
- Published
- 2023
- Full Text
- View/download PDF
23. Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults.
- Author
-
Weiser, Annette, Bergman, Astrid Sanchez, Machaalani, Charbel, Bennett, Julie, Roth, Patrick, Reimann, Regina R., Nazarian, Javad, and Stucklin, Ana S. Guerreiro
- Subjects
YOUNG adults ,CENTRAL nervous system tumors ,TEENAGERS ,GLIOMAS ,MOLECULAR pathology ,TUMOR classification - Abstract
Gliomas are the most common primary central nervous system (CNS) tumors and a major cause of cancer-related mortality in children (age <15 years), adolescents and young adults (AYA, ages 15-39 years), and adults (age >39 years). Molecular pathology has helped enhance the characterization of these tumors, revealing a heterogeneous and ever more complex group of malignancies. Recent molecular analyses have led to an increased appreciation of common genomic alterations prevalent across all ages. The 2021 World Health Organization (WHO) CNS tumor classification, 5th edition (WHO CNS5) brings forward a nomenclature distinguishing "pediatric-type" and "adult-type" gliomas. The spectrum of gliomas in AYA comprises both "pediatric-like" and "adult-like" tumor entities but remains ill-defined. With fragmentation of clinical management between pediatric and adult centers, AYAs face challenges related to gaps in medical care, lower rates of enrollment in clinical trials and additional psychosocial and economic challenges. This calls for a rethinking of diagnostic and therapeutic approaches, to improve access to appropriate testing and potentially beneficial treatments to patients of all ages. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
- Author
-
Setola, Elisabetta, Benini, S., Righi, A., Gamberi, G., Carretta, E., Ferrari, C., Avnet, S., Palmerini, E., Magagnoli, G., Gambarotti, M., Lollini, P. L., Cesari, M., Cocchi, S., Paioli, A., Longhi, A., Scotlandi, K., Laginestra, M. A., Donati, D. M., Baldini, N., and Ibrahim, T.
- Abstract
Background: Heterozygous isocitrate dehydrogenase (IDH) mutations occur in about half of conventional central bone chondrosarcomas (CCBC). Aim of this study was to assess the frequency and prognostic impact of IDH mutations in high grade CCBC patients. Methods: 64 patients with G2 and G3 CCBC were included. DNA extraction, PCR amplification of IDH1/2 exon 4s, and sequencing analysis with Sanger were performed. Results: IDH mutations were detected in 24/54 patients (44%): IDH1 in 18, IDH2 in 4, and both IDH1/2 in 2 patients. The frequency of mutations was 37% in G2 vs. 69% in G3 (p = 0.039), and 100% in three Ollier disease associated chondrosarcoma. 5-year overall survival (OS) at 124 months (range 1-166) was 51%, with no significant difference based on the IDH mutational status: 61% in IDHmut vs. 44% in IDH wild type (IDHwt). The 5-year relapse free survival (RFS) was 33% (95% CI:10–57) for IDHmut vs. 57% (95%CI: 30–77) for IDHwt. Progression free survival (PFS) was 25% (95%CI:1–65) IDHmut vs. 16% (95%CI: 0.7–52) IDHwt. 55% (5/9) of IDHmut G2 became higher grade at the recurrence, as compared with 25% (3/12) of G2 IDHwt. Conclusions: This study shows a higher frequency of IDH mutations in G3 CCBC as compared with G2. No significant differences in OS, RFS, and PFS by mutational status were detected. After relapse, a higher rate of G3 for IDH mutated CCBC was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma
- Author
-
Bayer and Kalil Abdullah, Assistant Professor
- Published
- 2022
26. Partial erosion on under-methylated regions and chromatin reprogramming contribute to oncogene activation in IDH mutant gliomas
- Author
-
Xinyu Wang, Lijun Dai, Yang Liu, Chenghao Li, Dandan Fan, Yue Zhou, Pengcheng Li, Qingran Kong, and Jianzhong Su
- Subjects
DNA methylation ,Chromatin ,Oncogene ,IDH mutation ,Glioma ,Genetics ,QH426-470 - Abstract
Abstract Background IDH1/2 hotspot mutations are well known to drive oncogenic mutations in gliomas and are well-defined in the WHO 2021 classification of central nervous system tumors. Specifically, IDH mutations lead to aberrant hypermethylation of under-methylated regions (UMRs) in normal tissues through the disruption of TET enzymes. However, the chromatin reprogramming and transcriptional changes induced by IDH-related hypermethylation in gliomas remain unclear. Results Here, we have developed a precise computational framework based on Hidden Markov Model to identify altered methylation states of UMRs at single-base resolution. By applying this framework to whole-genome bisulfite sequencing data from 75 normal brain tissues and 15 IDH mutant glioma tissues, we identified two distinct types of hypermethylated UMRs in IDH mutant gliomas. We named them partially hypermethylated UMRs (phUMRs) and fully hypermethylated UMRs (fhUMRs), respectively. We found that the phUMRs and fhUMRs exhibit distinct genomic features and chromatin states. Genes related to fhUMRs were more likely to be repressed in IDH mutant gliomas. In contrast, genes related to phUMRs were prone to be up-regulated in IDH mutant gliomas. Such activation of phUMR genes is associated with the accumulation of active H3K4me3 and the loss of H3K27me3, as well as H3K36me3 accumulation in gene bodies to maintain gene expression stability. In summary, partial erosion on UMRs was accompanied by locus-specific changes in key chromatin marks, which may contribute to oncogene activation. Conclusions Our study provides a computational strategy for precise decoding of methylation encroachment patterns in IDH mutant gliomas, revealing potential mechanistic insights into chromatin reprogramming that contribute to oncogenesis.
- Published
- 2023
- Full Text
- View/download PDF
27. Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd (TAC-GReD)
- Published
- 2021
28. PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial.
- Author
-
Bao, Zhaoshi, Li, Shouwei, Wang, Liang, Zhang, Bisi, Zhang, Peilong, Shi, Hepeng, Qiu, Xiaoguang, and Jiang, Tao
- Subjects
GENE fusion ,RESEARCH protocols ,PROGRESSION-free survival ,GLIOMAS ,GLIOBLASTOMA multiforme - Abstract
Background: PTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma, which was a target by a MET inhibitor vebreltinib. However, little is known about the further efficacy of vebreltinib among more glioma patients. This trial aims to evaluate the safety and efficacy of vebreltinib enteric-coated capsules in the treatment of sGBM/IDH mutant glioblastoma patients with the ZM fusion gene. Methods: This multicentric, randomized, open-label, controlled trial plans to include 19 neurosurgical centers and recruit 84 sGBM or IDH mutant glioblastoma patients with the ZM fusion gene. This trial enrolls sGBM or IDH mutant glioblastoma patients with the inclusion criteria and without the exclusion criteria. It was registered with chinadrugtrials.org.cn (CTR20181664). The primary efficacy endpoint is overall survival (OS). The secondary endpoints are progression-free survival (PFS) and objective response rate (ORR). Discussion: If proven effective, this targeted multifaceted intervention protocol will be extended for more glioma patients as a protocol to evaluate the safety and efficacy of MET inhibitors. Trial registration: It was registered with chinadrugtrials.org.cn (CTR20181664). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score.
- Author
-
Dao Trong, Philip, Kilian, Samuel, Jesser, Jessica, Reuss, David, Aras, Fuat Kaan, Von Deimling, Andreas, Herold-Mende, Christel, Unterberg, Andreas, and Jungk, Christine
- Subjects
- *
GLIOMAS , *REGRESSION analysis , *DESCRIPTIVE statistics , *DISEASE prevalence , *TUMOR grading - Abstract
Simple Summary: The preoperative risk estimation of non-enhancing suspected "low-grade" glioma (NEG) is key in determining the optimal timing of diagnosis and treatment to delay malignant progression and avoid undertreatment. The updated 2021 WHO classification brought new facets to glioma grading. Therefore, we sought to identify preoperative risk factors of malignancy in NEG by considering molecular criteria, including IDH mutation and CDKN2A/B deletion status. A total of 72 NEG patients were analyzed, and a high prevalence of malignant gliomas was detected considering both the traditional WHO grading (WHO grade 3 + 4) and the integrated molecular classification (IDHwt glioblastoma WHO grade 4 and IDHmut astrocytoma WHO grade 4). Easily determinable preoperative factors (age, T2/FLAIR mismatch sign, and SVZ involvement) were identified by uni- and multivariate analyses and incorporated into a score. The score estimates the probability of an NEG harboring a malignant glioma. Finally, the score was validated in a cohort of 40 NEG patients and proved to be a better prediction model than the Pignatti score or the T2/FLAIR mismatch sign. The preoperative grading of non-enhancing glioma (NEG) remains challenging. Herein, we analyzed clinical and magnetic resonance imaging (MRI) features to predict malignancy in NEG according to the 2021 WHO classification and developed a clinical score, facilitating risk estimation. A discovery cohort (2012–2017, n = 72) was analyzed for MRI and clinical features (T2/FLAIR mismatch sign, subventricular zone (SVZ) involvement, tumor volume, growth rate, age, Pignatti score, and symptoms). Despite a "low-grade" appearance on MRI, 81% of patients were classified as WHO grade 3 or 4. Malignancy was then stratified by: (1) WHO grade (WHO grade 2 vs. WHO grade 3 + 4) and (2) molecular criteria (IDHmut WHO grade 2 + 3 vs. IDHwt glioblastoma + IDHmut astrocytoma WHO grade 4). Age, Pignatti score, SVZ involvement, and T2/FLAIR mismatch sign predicted malignancy only when considering molecular criteria, including IDH mutation and CDKN2A/B deletion status. A multivariate regression confirmed age and T2/FLAIR mismatch sign as independent predictors (p = 0.0009; p = 0.011). A "risk estimation in non-enhancing glioma" (RENEG) score was derived and tested in a validation cohort (2018–2019, n = 40), yielding a higher predictive value than the Pignatti score or the T2/FLAIR mismatch sign (AUC of receiver operating characteristics = 0.89). The prevalence of malignant glioma was high in this series of NEGs, supporting an upfront diagnosis and treatment approach. A clinical score with robust test performance was developed that identifies patients at risk for malignancy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas
- Author
-
Yanwei Liu, Huiyuan Chen, Guanzhang Li, Jing Zhang, Kun Yao, Chenxing Wu, Shouwei Li, and Xiaoguang Qiu
- Subjects
lower-grade gliomas ,idh mutation ,radiotherapy ,malignant transformation ,survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective: IDH-mutant lower-grade gliomas (LGGs, grade 2 or 3) eventually transform into secondary grade 4 astrocytomas (sAIDHmut/G4). Here, we sought to describe the transformation time, risk factors, and outcomes in malignant transformation of IDH-mutant LGGs. Methods: We screened data for 108 patients with sAIDHmut/G4 in the Chinese Glioma Genome Atlas who had initial IDH-mutant LGGs and underwent reoperation during 2005–2021. We evaluated the transformation time from IDH-mutant LGGs to sAIDHmut/G4, and associated risk factors and outcomes. Malignant transformation was defined as pathological confirmation of grade 4 astrocytoma. Results: The median age of the 108 patients with IDH-mutant LGGs was 35 years (range, 19–54); the median age at transformation was 40 years (range, 25–62); and the median follow-up time for all patients was 146 months (range, 121–171). The average transformation time was 58.8 months for all patients with LGGs (range, 5.9–208.1); 63.5 and 51.9 months for grade 2 and 3 gliomas, respectively; and 58.4 and 78.1 months for IDH-mutant/1p/19q-non-codeleted astrocytomas and IDH-mutant/1p/19q-codeleted oligodendrogliomas, respectively. Univariate and multivariate analysis indicated that radiotherapy [hazard ratio (HR), 0.29; 95% confidence interval (CI), 0.137–0.595; P = 0.001] and non-A blood type (HR, 0.37; 95% CI, 0.203–0.680; P = 0.001) were protective factors against delayed malignant transformation. Radiotherapy was associated with improved survival after transformation (HR, 0.44; 95% CI, 0.241–0.803; P = 0.008), overall survival (HR, 0.50; 95% CI, 0.265–0.972; P = 0.041), and progression-free survival (HR, 0.25; 95% CI, 0.133–0.479; P < 0.0001) in patients with IDH-mutant gliomas. Conclusions: Radiotherapy is associated with delayed malignant transformation and improved survival in patients with IDH-mutant gliomas.
- Published
- 2022
- Full Text
- View/download PDF
31. A curious case of T2-FLAIR mismatch in H3K27M mutant glioma
- Author
-
William L. Valentino, MD, MS, Darren Okada, MD, and Shiv Bhanu, MD
- Subjects
T2-FLAIR mismatch ,Adult brainstem glioma ,Diffuse midline glioma ,H3K27M mutation ,IDH mutation ,Astrocytoma ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Diffuse midline gliomas are a rare relatively new classification of primary central nervous system tumors which include astrocytomas, oligodendrogliomas, and glioblastomas. The T2-FLAIR mismatch sign is regarded as a highly specific imaging feature of IDH-mutant, 1p/19q non-codeleted astrocytomas. The case presented herein demonstrates this sign, however, in a non-IDH mutated diffuse midline glioma with a H3K27M mutation, a World Health Organization Grade IV neoplasm. Although preoperative diagnosis can provide important treatment and prognostic information, it is often quite difficult particularly in primary central nervous system tumors.
- Published
- 2022
- Full Text
- View/download PDF
32. Partial erosion on under-methylated regions and chromatin reprogramming contribute to oncogene activation in IDH mutant gliomas.
- Author
-
Wang, Xinyu, Dai, Lijun, Liu, Yang, Li, Chenghao, Fan, Dandan, Zhou, Yue, Li, Pengcheng, Kong, Qingran, and Su, Jianzhong
- Subjects
- *
GLIOMAS , *EPIGENOMICS , *CHROMATIN , *HIDDEN Markov models , *ONCOGENES , *GENE expression , *P16 gene ,CENTRAL nervous system tumors - Abstract
Background: IDH1/2 hotspot mutations are well known to drive oncogenic mutations in gliomas and are well-defined in the WHO 2021 classification of central nervous system tumors. Specifically, IDH mutations lead to aberrant hypermethylation of under-methylated regions (UMRs) in normal tissues through the disruption of TET enzymes. However, the chromatin reprogramming and transcriptional changes induced by IDH-related hypermethylation in gliomas remain unclear. Results: Here, we have developed a precise computational framework based on Hidden Markov Model to identify altered methylation states of UMRs at single-base resolution. By applying this framework to whole-genome bisulfite sequencing data from 75 normal brain tissues and 15 IDH mutant glioma tissues, we identified two distinct types of hypermethylated UMRs in IDH mutant gliomas. We named them partially hypermethylated UMRs (phUMRs) and fully hypermethylated UMRs (fhUMRs), respectively. We found that the phUMRs and fhUMRs exhibit distinct genomic features and chromatin states. Genes related to fhUMRs were more likely to be repressed in IDH mutant gliomas. In contrast, genes related to phUMRs were prone to be up-regulated in IDH mutant gliomas. Such activation of phUMR genes is associated with the accumulation of active H3K4me3 and the loss of H3K27me3, as well as H3K36me3 accumulation in gene bodies to maintain gene expression stability. In summary, partial erosion on UMRs was accompanied by locus-specific changes in key chromatin marks, which may contribute to oncogene activation. Conclusions: Our study provides a computational strategy for precise decoding of methylation encroachment patterns in IDH mutant gliomas, revealing potential mechanistic insights into chromatin reprogramming that contribute to oncogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States.
- Author
-
Neff, Corey, Cioffi, Gino, Waite, Kristin, Kruchko, Carol, Barnholtz-Sloan, Jill S, Ostrom, Quinn T, and Iorgulescu, J Bryan
- Subjects
- *
GLIOMAS , *BRAIN tumors , *COMMUNITY centers , *GLIOBLASTOMA multiforme , *ASTROCYTOMAS , *O6-Methylguanine-DNA Methyltransferase - Abstract
Background A newly developed brain molecular marker (BMM) data item was implemented by US cancer registries for individuals diagnosed with brain tumors in 2018—including IDH and 1p/19q-co-deletion statuses for adult-type diffuse gliomas. We thus investigated the testing/reporting completeness of BMM in the United States. Methods Cases of histopathologically confirmed glioblastoma, astrocytoma, and oligodendroglioma diagnosed in 2018 were identified in the National Cancer Database. Adjusted odds ratios (ORadj) and 95% confidence intervals (CI) of BMM testing/reporting were evaluated for association with the selected patient, treatment, and facility-level characteristics using multivariable logistic regression. As a secondary analysis, predictors of MGMT promoter methylation testing/reporting among IDH-wildtype glioblastoma individuals were assessed. Key limitations of the BMM data item were that it did not include any details regarding testing technique or assay type and could not distinguish between a lack of testing and a lack of cancer registry reporting of testing results. Results Among 8306 histopathologically diagnosed adult-type diffuse gliomas nationally, overall BMM testing/reporting completeness was 81.1%. Compared to biopsy-only cases, odds of testing/reporting increased for subtotal (ORadj= 1.38 [95% CI: 1.20–1.59], P <.001) and gross total resection (ORadj=1.50 [95% CI: 1.31–1.72], P <.001). Furthermore, the odds were lowest at community centers (hospitals (67.3%; ORadj=0.35 [95% CI: 0.26–0.46], P <.001) and highest at academic/NCI-designated comprehensive cancer centers (85.4%; referent). By geographical location, BMM testing/reporting completeness ranged from a high of 86.8% at New England (referent) to a low of 76.0 % in the West South Central region (ORadj=0.57 [95% CI: 0.42–0.78]; P <.001). Extent of resection, Commission-on-Cancer facility type, and facility location were additionally significant predictors of MGMT testing/reporting among IDH-wildtype glioblastoma cases. Conclusions Initial BMM testing/reporting completeness for individuals with adult-type diffuse gliomas in the United States was promising, although patterns varied by hospital attributes and extent of resection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Treating oligodendroglioma – An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort
- Author
-
Luisa Allwohn, Josy Wolfgang, Julia Onken, David Wasilewski, Siyer Roohani, Daniel Zips, Felix Ehret, and David Kaul
- Subjects
Oligodendroglioma ,Radiochemotherapy ,Temozolomide ,PCV ,IDH mutation ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Oligodendrogliomas (ODG) are rare, diffusely infiltrating brain tumors, defined by their 1p/19q-codeletion and isocitrate dehydrogenase (IDH) mutation. Herein, we analyze the influence of various tumor and patient characteristics on progression-free survival (PFS) and overall survival (OS) in a homogeneous patient cohort. Material and methods: Patients treated for a 1p/19q-codeleted and IDH-mutant ODG were evaluated. The patient and tumor characteristics were analyzed for their influence on PFS and OS. Results: One-hundred-fourteen patients met the inclusion criteria. The median clinical and radiographic follow-up periods were 68.6 and 69.8 months. The median PFS and OS were 66.9 and 236.0 months, respectively. The 2-, 4- and 6-year PFS rates were 89.5%, 76.3%, and 46.0%. The 2-, 4- and 6-year OS rates were 99.0%, 97.9%, and 96.2%. For WHO grade 2 ODG, extent of resection (p = 0.01, hazard ratio (HR) 0.01; p = 0.02, HR 0.02), radiotherapy (p = 0.01, HR
- Published
- 2023
- Full Text
- View/download PDF
35. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus
- Author
-
Schiff, David, Van den Bent, Martin, Vogelbaum, Michael A, Wick, Wolfgang, Miller, C Ryan, Taphoorn, Martin, Pope, Whitney, Brown, Paul D, Platten, Michael, Jalali, Rakesh, Armstrong, Terri, and Wen, Patrick Y
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Brain Disorders ,Brain Cancer ,Rare Diseases ,Biomedical Imaging ,Neurosciences ,Cancer ,Adult ,Brain Neoplasms ,Combined Modality Therapy ,Europe ,Glioma ,Humans ,Neoplasm Grading ,Neuroimaging ,Prognosis ,Societies ,Medical ,astrocytoma ,glioma ,IDH mutation ,lower-grade ,oligodendroglioma ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and deletional analysis of cyclin-dependent kinase inhibitor 2A and 2B. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Recent, ongoing, and planned studies of radiation therapy and both cytotoxic and targeted chemotherapies are summarized, including both small molecule and immunotherapy approaches specifically targeting the mutant IDH protein.
- Published
- 2019
36. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts
- Author
-
Lee, Julieann, Putnam, Angelica R, Chesier, Samuel H, Banerjee, Anuradha, Raffel, Corey, Van Ziffle, Jessica, Onodera, Courtney, Grenert, James P, Bastian, Boris C, Perry, Arie, and Solomon, David A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Good Health and Well Being ,Adolescent ,Brain Neoplasms ,Child ,Chromosomes ,Human ,Pair 19 ,Female ,Humans ,Isocitrate Dehydrogenase ,Male ,Mutation ,Oligodendroglioma ,Promoter Regions ,Genetic ,Telomerase ,IDH mutation ,1p/19q-codeletion ,Teenager ,Pediatric ,TERT promoter ,FGFR1 ,CIC ,IDH1 ,Molecular neuro-oncology ,Biochemistry and Cell Biology ,Neurosciences ,Biochemistry and cell biology - Published
- 2018
37. Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH -Mutant Gliomas: A French POLA Network Study.
- Author
-
Montégut, Coline, Guillamo, Jean-Sébastien, Ducray, François, Dehais, Caroline, Cohen-Jonathan Moyal, Elisabeth, Desenclos, Christine, Petit, Antoine, Seizeur, Romuald, Bekaert, Lien, Gaultier, Claude, Motuo Fotso, Marie Jeannette, Blonski, Marie, Frenel, Jean-Sébastien, Vauléon, Elodie, Langlois, Olivier, Noel, Georges, Carpentier, Antoine F., Di Stefano, Anna Luisa, Bronnimann, Charlotte, and Figarella-Branger, Dominique
- Subjects
- *
GLIOMA treatment , *GERIATRIC assessment , *DESCRIPTIVE statistics , *PROGRESSION-free survival , *ELDER care , *OLD age - Abstract
Simple Summary: Gliomas remain the most common primary brain tumor in adults. Although they are classified based on the IDH mutation status very little is known considering this alteration in the elderly glioma population. Because IDH-mutated gliomas are associated with better prognosis in the young population, it is essential to characterize its role in elderly and more frail patients to help physicians' therapeutic decisions. In this study, we demonstrated that elderly IDH-mutated gliomas had very similar characteristics to those found in the younger population but were significantly different from elderly IDH wild-type gliomas. However, patient management in this population appeared to be suboptimal, with less frequent gross total resection and irradiation. We showed that an optimal therapeutic combination of radio-chemotherapy could be safe and feasible for these elderly patients to aid in their management. Finally, we identified specific geriatric prognostic factors such as mobility, neuropsychological disorders, body mass index, and autonomy that can help physicians make future therapeutic decisions for this specific elderly population with a better prognosis. Background: Describe the characteristics, patterns of care, and predictive geriatric factors of elderly patients with IDHm high-grade glioma (HGG) included in the French POLA network. Material and Methods: The characteristics of elderly (≥70 years) patients IDHm HGG were compared to those of younger patients IDHm HGG (<70 years) and of elderly patients IDHwt HGG. Geriatric features were collected. Results: Out of 1433 HGG patients included, 119 (8.3%) were ≥70 years. Among them, 39 presented with IDHm HGG. The main characteristics of elderly IDHm HGG were different from those of elderly IDHwt HGG but similar to those of younger IDHm HGG. In contrast, their therapeutic management was different from those of younger IDHm HGG with less frequent gross total resection and radiotherapy. The median progression-free survival (PFS) and overall survival (OS) were longer for elderly patients IDHm HGG (29.3 months and 62.1 months) than elderly patients IDHwt HGG (8.3 months and 13.3 months) but shorter than those of younger patients IDHm HGG (69.1 months and not reached). Geriatric factors associated with PFS and OS were mobility, neuropsychological disorders, body mass index, and autonomy. Geriatric factors associated with PFS and OS were mobility, neuropsychological disorders, and body mass index, and autonomy. Conclusion: the outcome of IDHm HGG in elderly patients is better than that of IDHwt HGG. Geriatric assessment may be particularly important to optimally manage these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study
- Author
-
Alexandra Clément, Timothee Zaragori, Romain Filosa, Olga Ovdiichuk, Marine Beaumont, Charlotte Collet, Emilie Roeder, Baptiste Martin, Fatiha Maskali, Muriel Barberi-Heyob, Celso Pouget, Matthieu Doyen, and Antoine Verger
- Subjects
IDH mutation ,PET ,Gliomas ,[18F]DPA-714 ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background This translational study explores multi-tracer PET imaging for the non-invasive detection of the IDH1 mutation which is a positive prognostic factor in glioma. Methods U87 human high-grade glioma (HGG) isogenic cell lines with or without the IDH1 mutation (CRISP/Cas9 method) were stereotactically grafted into rat brains, and examined, in vitro, in vivo and ex vivo. PET imaging sessions, with radiotracers specific for glycolytic metabolism ([18F]FDG), amino acid metabolism ([18F]FDopa), and inflammation ([18F]DPA-714), were performed sequentially during 3–4 days. The in vitro radiotracer uptake was expressed as percent per million cells. For each radiotracer examined in vivo, static analyses included the maximal and mean tumor-to-background ratio (TBRmax and TBRmean) and metabolic tumor volume (MTV). Dynamic analyses included the distribution volume ratio (DVR) and the relative residence time (RRT) extracted from a reference Logan model. Ex vivo analyses consisted of immunological analyses. Results In vitro, IDH1+ cells (i.e. cells expressing the IDH1 mutation) showed lower levels of [18F]DPA-714 uptake compared to IDH1- cells (p
- Published
- 2022
- Full Text
- View/download PDF
39. Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification
- Author
-
María del Mar Álvarez-Torres, Elies Fuster-García, Javier Juan-Albarracín, Gaspar Reynés, Fernando Aparici-Robles, Jaime Ferrer-Lozano, and Juan Miguel García-Gómez
- Subjects
Glioblastoma ,Relative blood volume ,DSC perfusion ,Microvascular proliferation ,IDH mutation ,Histopathology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The microvessels area (MVA), derived from microvascular proliferation, is a biomarker useful for high-grade glioma classification. Nevertheless, its measurement is costly, labor-intense, and invasive. Finding radiologic correlations with MVA could provide a complementary non-invasive approach without an extra cost and labor intensity and from the first stage. This study aims to correlate imaging markers, such as relative cerebral blood volume (rCBV), and local MVA in IDH-wildtype glioblastoma, and to propose this imaging marker as useful for astrocytoma grade 4 classification. Methods Data from 73 tissue blocks belonging to 17 IDH-wildtype glioblastomas and 7 blocks from 2 IDH-mutant astrocytomas were compiled from the Ivy GAP database. MRI processing and rCBV quantification were carried out using ONCOhabitats methodology. Histologic and MRI co-registration was done manually with experts’ supervision, achieving an accuracy of 88.8% of overlay. Spearman’s correlation was used to analyze the association between rCBV and microvessel area. Mann-Whitney test was used to study differences of rCBV between blocks with presence or absence of microvessels in IDH-wildtype glioblastoma, as well as to find differences with IDH-mutant astrocytoma samples. Results Significant positive correlations were found between rCBV and microvessel area in the IDH-wildtype blocks (p
- Published
- 2022
- Full Text
- View/download PDF
40. Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy
- Author
-
Gabrielle Metz, Dasantha Jayamanne, Helen Wheeler, Matthew Wong, Raymond Cook, Nicholas Little, Jonathon Parkinson, Marina Kastelan, Chris Brown, and Michael Back
- Subjects
Anaplastic glioma ,IDH mutation ,Residual volume ,Radiation therapy ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background The impact of near-total resection of IDH-mutated anaplastic glioma (IDHmutAG) is well-established but there remains uncertainty of benefit in tumours of the insular cortex where the extent of safe resection may be limited. This study aimed to assess tumour volume reduction in patients following IMRT and impact of residual post-surgical volume. Methods and materials Patients with IDHmutAG involving insular cortex managed with IMRT from 2008 to 2019 had baseline patient, tumour and treatment factors recorded. Volumetric assessment of residual disease on MRI was performed at baseline, month+ 3 and month+ 12 post-IMRT. Potential prognostic factors were analysed for tumour reduction and relapse-free survival, and assessed by log-rank and Cox regression analyses. Results Thirty two patients with IDHmutAG of the insular cortex were managed with median follow-up post-IMRT of 67.2 months. Pathology was anaplastic astrocytoma (AAmut) in 20, and anaplastic oligodendroglioma (AOD) in 12 patients. Median pre-IMRT volume on T1 and T2Flair was 24.3cm3 and 52.2cm3. Twenty-seven patients were alive with 5-year relapse-free survival of 80%. There was a median 67 and 64% reduction from baseline occurring at 3 months post-IMRT for T1 and T2Flair respectively; and subsequent median 78 and 73% at 12 months. At 12 months AOD patients had median 83% T1 volume reduction compared to 63% in AAmut (p
- Published
- 2022
- Full Text
- View/download PDF
41. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status
- Author
-
Delfanti, Rachel L, Piccioni, David E, Handwerker, Jason, Bahrami, Naeim, Krishnan, AnithaPriya, Karunamuni, Roshan, Hattangadi-Gluth, Jona A, Seibert, Tyler M, Srikant, Ashwin, Jones, Karra A, Snyder, Vivian S, Dale, Anders M, White, Nathan S, McDonald, Carrie R, and Farid, Nikdokht
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Brain Cancer ,Orphan Drug ,Clinical Research ,Rare Diseases ,Brain Disorders ,Cancer ,Clinical Trials and Supportive Activities ,Neurosciences ,Biomedical Imaging ,Adult ,Brain ,Brain Neoplasms ,Chromosomes ,Human ,Pair 1 ,Disease-Free Survival ,Female ,Follow-Up Studies ,Glioma ,Humans ,Isocitrate Dehydrogenase ,Kaplan-Meier Estimate ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Mutation ,Neoplasm Grading ,Proportional Hazards Models ,Retrospective Studies ,World Health Organization ,X-linked Nuclear Protein ,Lower grade gliomas ,Grade II/III gliomas ,IDH mutation ,Neuroradiology ,MRI ,Radiogenomics ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
The 2016 World Health Organization Classification of Tumors of the Central Nervous System incorporates the use of molecular information into the classification of brain tumors, including grade II and III gliomas, providing new prognostic information that cannot be delineated based on histopathology alone. We hypothesized that these genomic subgroups may also have distinct imaging features. A retrospective single institution study was performed on 40 patients with pathologically proven infiltrating WHO grade II/III gliomas with a pre-treatment MRI and molecular data on IDH, chromosomes 1p/19q and ATRX status. Two blinded Neuroradiologists qualitatively assessed MR features. The relationship between each parameter and molecular subgroup (IDH-wildtype; IDH-mutant-1p/19q codeleted-ATRX intact; IDH-mutant-1p/19q intact-ATRX loss) was evaluated with Fisher's exact test. Progression free survival (PFS) was also analyzed. A border that could not be defined on FLAIR was most characteristic of IDH-wildtype tumors, whereas IDH-mutant tumors demonstrated either well-defined or slightly ill-defined borders (p = 0.019). Degree of contrast enhancement and presence of restricted diffusion did not distinguish molecular subgroups. Frontal lobe predominance was associated with IDH-mutant tumors (p = 0.006). The IDH-wildtype subgroup had significantly shorter PFS than the IDH-mutant groups (p
- Published
- 2017
42. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
- Author
-
Tang, Feng, Pan, Zhiyong, Wang, Yi, Lan, Tian, Wang, Mengyue, Li, Fengping, Quan, Wei, Liu, Zhenyuan, Wang, Zefen, and Li, Zhiqiang
- Abstract
Isocitrate dehydrogenase (IDH) is an essential metabolic enzyme in the tricarboxylic acid cycle (TAC). The high mutation frequency of the IDH gene plays a complicated role in gliomas. In addition to affecting gliomas directly, mutations in IDH can also alter their immune microenvironment and can change immune-cell function in direct and indirect ways. IDH mutations mediate immune-cell infiltration and function by modulating immune-checkpoint gene expression and chemokine secretion. In addition, IDH mutation-derived D2-hydroxyglutarate can be absorbed by surrounding immune cells, also affecting their functioning. In this review, we summarize current knowledge about the effects of IDH mutations as well as other gene mutations on the immune microenvironment of gliomas. We also describe recent preclinical and clinical data related to IDH-mutant inhibitors for the treatment of gliomas. Finally, we discuss different types of immunotherapy and the immunotherapeutic potential of IDH mutations in gliomas. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. Critical Response: “Does the Mutation of Cancer Driver Genes IDH1/2 and CD204 Influence Cancer Metabolism and Tumor Associated Macrophage Recruitment in Tumor Microenvironment” [Letter]
- Author
-
Panjaitan NSD, Handayani S, and Dewi RM
- Subjects
idh mutation ,cd204 mutation ,tumor associated macrophage ,cancer metabolism ,tumor microenvironment ,Medicine (General) ,R5-920 - Abstract
Novaria Sari Dewi Panjaitan, Sarwo Handayani, Rita Marleta Dewi Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, West Java, IndonesiaCorrespondence: Novaria Sari Dewi Panjaitan, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Jl. Raya Bogor No. 490, Cibinong – Bogor Km. 46, Bogor, West Java, Indonesia, Email nova014@brin.go.id
- Published
- 2023
44. The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers.
- Author
-
Skoblar Vidmar, Marija, Doma, Andrej, Smrdel, Uroš, Zevnik, Katarina, and Studen, Andrej
- Subjects
- *
RELATIONSHIP status , *GLIOMAS , *POSITRON emission tomography , *ISOCITRATE dehydrogenase - Abstract
The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[18F] fluoroethyl-)-L-tyrosine (18F-FET) has been shown to be a useful tool for detecting TRC and TP. We assessed the diagnostic performance of different 18F-FET PET segmentation approaches and different imaging biomarkers for differentiation between late TRC and TP in glioma patients. Isocitrate dehydrogenase (IDH) status was evaluated as a predictor of disease outcome. In our study, the proportion of TRC in IDH wild type (IDHwt) and IDH mutant (IDHm) subgroups was without significant difference. We found that the diagnostic value of static and dynamic biomarkers of 18F-FET PET for discrimination between TRC and TP depends on the IDH mutation status of the tumor. Dynamic 18F-FET PET acquisition proved helpful in the IDH wild type (IDHwt) subgroup, as opposed to the IDH mutant (IDHm) subgroup, providing an early indication to discontinue dynamic imaging in the IDHm subgroup. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo 1 H-Magnetic Resonance Spectroscopy and Machine Learning.
- Author
-
Bumes, Elisabeth, Fellner, Claudia, Fellner, Franz A., Fleischanderl, Karin, Häckl, Martina, Lenz, Stefan, Linker, Ralf, Mirus, Tim, Oefner, Peter J., Paar, Christian, Proescholdt, Martin Andreas, Riemenschneider, Markus J., Rosengarth, Katharina, Weis, Serge, Wendl, Christina, Wimmer, Sibylle, Hau, Peter, Gronwald, Wolfram, and Hutterer, Markus
- Subjects
- *
SUPPORT vector machines , *GENETIC mutation , *IN vivo studies , *CONFIDENCE intervals , *PROTON magnetic resonance spectroscopy , *RESEARCH methodology , *GLIOMAS , *MACHINE learning , *RETROSPECTIVE studies , *ACQUISITION of data , *CANCER patients , *DESCRIPTIVE statistics , *MEDICAL records , *OXIDOREDUCTASES , *COMPUTER-aided diagnosis , *PREDICTION models , *SENSITIVITY & specificity (Statistics) - Abstract
Simple Summary: The enzyme isocitrate dehydrogenase (IDH) affects glioma cell metabolism in multiple ways. Mutation of IDH is not only indicative of the presence of astrocytoma or oligodendroglioma but it also comes with a better prognosis and constitutes a promising therapeutic target. Therefore, determination of IDH mutation status is essential in clinical practice. In most patients, tissue can be obtained by resection or biopsy to determine IDH status histologically. However, in some cases, this is not possible for technical reasons. We recently showed in a small cohort of patients that non-invasive determination of IDH mutation status using proton magnetic resonance spectroscopy (1H-MRS) at 3.0 Tesla (T) together with machine learning techniques is feasible in a standard clinical setting and with acceptable effort. Here, we demonstrate that our approach showed comparably good results in sensitivity (82.6%) and specificity (72.7%) in a larger validation cohort employing 1H-MRS at 1.5 T in a retrospective, distinct setting. We concluded that our method works well regardless of the magnetic field strength and scanner used, and thus, may improve patient care. The isocitrate dehydrogenase (IDH) mutation status is an indispensable prerequisite for diagnosis of glioma (astrocytoma and oligodendroglioma) according to the WHO classification of brain tumors 2021 and is a potential therapeutic target. Usually, immunohistochemistry followed by sequencing of tumor tissue is performed for this purpose. In clinical routine, however, non-invasive determination of IDH mutation status is desirable in cases where tumor biopsy is not possible and for monitoring neuro-oncological therapies. In a previous publication, we presented reliable prediction of IDH mutation status employing proton magnetic resonance spectroscopy (1H-MRS) on a 3.0 Tesla (T) scanner and machine learning in a prospective cohort of 34 glioma patients. Here, we validated this approach in an independent cohort of 67 patients, for which 1H-MR spectra were acquired at 1.5 T between 2002 and 2007, using the same data analysis approach. Despite different technical conditions, a sensitivity of 82.6% (95% CI, 61.2–95.1%) and a specificity of 72.7% (95% CI, 57.2–85.0%) could be achieved. We concluded that our 1H-MRS based approach can be established in a routine clinical setting with affordable effort and time, independent of technical conditions employed. Therefore, the method provides a non-invasive tool for determining IDH status that is well-applicable in an everyday clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Clinical Profile, Pathology, and Molecular Typing of Gliomas with Oligodendroglial Morphology: A Single Institutional Experience.
- Author
-
Lavanya, Garapati, Uppin, Megha, Alugolu, Rajesh, Bhattacharjee, Suchanda, Saradhi, Mudumba, Yeramneni, Vamsi, Uppin, Megha Shantveer, Saradhi, Mudumba Vijaya, and Yeramneni, Vamsi Krishna
- Subjects
- *
CHROMOSOMES , *GENETIC mutation , *GLIOMAS , *FLUORESCENCE in situ hybridization , *OXIDOREDUCTASES , *GENETIC techniques ,BRAIN tumor diagnosis - Abstract
Background: Diffuse gliomas are represented in the 2007 WHO classification of CNS tumors as astrocytomas, oligoastrocytoma, and oligodendroglioma of grades II/III and glioblastomas WHO grade IV, which was a pure morphologic classification. WHO 2016 classification combines morphology with molecular markers like IDH, ATRX, and 1p/19q codeletion to give an integrated diagnosis.Methods: The study was carried out on formalin fixed paraffin embedded tissues from 54 patients including three pediatric patients. Molecular studies were performed to know the 1p/19q codeletion status, IDH1R132H, and ATRX immunoexpression. Also, the IDH1R132H status was correlated with survival data.Results: The study included 54 tumors with oligodendroglial morphology. IDH1R132H positivity was seen in 85% of total cases and codeletion was seen in 72%. The integrated diagnosis revised the cases into oligodendroglioma (39), astrocytoma (5), and glioblastoma (6).IDH mutant tumors were found to have better survival than negative ones which was statistically significant.Conclusion: This study emphasizes the need for molecular work up of tumors with oligodendroglial morphology with readily available techniques like IHC and Fluorescence in situ hybridization. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
47. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
- Author
-
Kenta Suzuki, Nobuyuki Kawai, Tomoya Ogawa, Keisuke Miyake, Aya Shinomiya, Yuka Yamamoto, Yoshihiro Nishiyama, and Takashi Tamiya
- Subjects
Chromosome 1p and 19q codeletion ,[18F]-Fluoromisonidazole (FMISO) ,[18F]-Fluoro-2-deoxy-d-glucose (FDG) ,Glioma ,IDH mutation ,Hypoxia ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background Tumor hypoxia and glycolysis have been recognized as determinant factors characterizing tumor aggressiveness in malignant gliomas. To clarify in vivo hypoxia and glucose metabolism in relation to isocitrate dehydrogenase (IDH) mutation and chromosome 1p and 19q (1p/19q) codeletion status, we retrospectively analyzed hypoxia as assessed by positron emission tomography (PET) with [18F]-fluoromisonidazole (FMISO) and glucose metabolism as assessed by PET with [18F]-fluoro-2-deoxy-d-glucose (FDG) in newly diagnosed malignant gliomas. Methods In total, 87 patients with newly diagnosed supratentorial malignant (WHO grade III and IV) gliomas were enrolled in this study. They underwent PET studies with FMISO and FDG before surgery. The molecular features and histopathological diagnoses based on the 2016 WHO classification were determined using surgical specimens. Maximal tumor-to-normal ratio (TNR) was calculated for FDG PET, and maximal tumor-to-blood SUV ratio (TBR) was calculated for FMISO PET. The PET uptake values in relation to IDH mutation and 1p/19q codeletion status were statistically analyzed. Results In all tumors and malignant astrocytomas, the median FMISO TBR in IDH-wildtype tumors was significantly higher than that in IDH-mutant tumors (P
- Published
- 2021
- Full Text
- View/download PDF
48. Identifying α-KG-dependent prognostic signature for lower-grade glioma based on transcriptome profiles
- Author
-
Tan Zhang, Liqun Yuan, Minfeng Sheng, Yanming Chen, Ji Wang, and Qing Lan
- Subjects
IDH mutation ,α-KG ,2-HG ,lower-grade glioma ,genome-wide analysis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The inhibition of alpha-ketoglutarate (α-KG)-dependent dioxygenases is thought to contribute to isocitrate dehydrogenase (IDH) mutation-derived malignancy. Herein, we aim to thoroughly investigate the expression pattern and prognostic significance of genes encoding α-KG-dependent enzymes for lower-grade glioma (LGG) patients. In this retrospective study, a total of 775 LGG patients were enrolled. The generalized linear model, least absolute shrinkage and selection operator Cox regression, and nomogram were applied to identify the enzyme-based signature. With the use of gene set enrichment analysis and Gene Ontology, the probable molecular abnormalities underlying high-risk patients were investigated. By comprehensively analyzing mRNA data, we observed that 41 genes were differentially expressed between IDHMUT and IDHWT LGG patients. A risk signature comprising 10 genes, which could divide samples into high- and low-risk groups of distinct prognoses, was developed and independently validated. This enzyme-based signature was indicative of a more malignant phenotype. The nomogram model incorporating the risk signature, molecular biomarkers, and clinicopathological parameters proved the incremental utility of the α-KG-dependent signature by achieving a more accurate prediction impact. Our study demonstrates that the α-KG-dependent enzyme-encoding genes were differentially expressed in relation to the IDH phenotype and may serve as a promising indicator for clinical outcomes of LGG patients.
- Published
- 2022
- Full Text
- View/download PDF
49. Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
- Author
-
Hiroyuki Tatekawa, Akifumi Hagiwara, Hiroyuki Uetani, Shadfar Bahri, Catalina Raymond, Albert Lai, Timothy F. Cloughesy, Phioanh L. Nghiemphu, Linda M. Liau, Whitney B. Pope, Noriko Salamon, and Benjamin M. Ellingson
- Subjects
Machine learning ,18F-DOPA PET ,MRI ,IDH mutation ,Clustering ,Diffuse glioma ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The purpose of this study was to develop a voxel-wise clustering method of multiparametric magnetic resonance imaging (MRI) and 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) positron emission tomography (PET) images using an unsupervised, two-level clustering approach followed by support vector machine in order to classify the isocitrate dehydrogenase (IDH) status of gliomas. Methods Sixty-two treatment-naïve glioma patients who underwent FDOPA PET and MRI were retrospectively included. Contrast enhanced T1-weighted images, T2-weighted images, fluid-attenuated inversion recovery images, apparent diffusion coefficient maps, and relative cerebral blood volume maps, and FDOPA PET images were used for voxel-wise feature extraction. An unsupervised two-level clustering approach, including a self-organizing map followed by the K-means algorithm was used, and each class label was applied to the original images. The logarithmic ratio of labels in each class within tumor regions was applied to a support vector machine to differentiate IDH mutation status. The area under the curve (AUC) of receiver operating characteristic curves, accuracy, and F1-socore were calculated and used as metrics for performance. Results The associations of multiparametric imaging values in each cluster were successfully visualized. Multiparametric images with 16-class clustering revealed the highest classification performance to differentiate IDH status with the AUC, accuracy, and F1-score of 0.81, 0.76, and 0.76, respectively. Conclusions Machine learning using an unsupervised two-level clustering approach followed by a support vector machine classified the IDH mutation status of gliomas, and visualized voxel-wise features from multiparametric MRI and FDOPA PET images. Unsupervised clustered features may improve the understanding of prioritizing multiparametric imaging for classifying IDH status.
- Published
- 2021
- Full Text
- View/download PDF
50. Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score
- Author
-
Philip Dao Trong, Samuel Kilian, Jessica Jesser, David Reuss, Fuat Kaan Aras, Andreas Von Deimling, Christel Herold-Mende, Andreas Unterberg, and Christine Jungk
- Subjects
non-enhancing glioma ,lower-grade glioma ,malignant glioma ,IDH mutation ,CDKN2A/B ,molecular classification ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The preoperative grading of non-enhancing glioma (NEG) remains challenging. Herein, we analyzed clinical and magnetic resonance imaging (MRI) features to predict malignancy in NEG according to the 2021 WHO classification and developed a clinical score, facilitating risk estimation. A discovery cohort (2012–2017, n = 72) was analyzed for MRI and clinical features (T2/FLAIR mismatch sign, subventricular zone (SVZ) involvement, tumor volume, growth rate, age, Pignatti score, and symptoms). Despite a “low-grade” appearance on MRI, 81% of patients were classified as WHO grade 3 or 4. Malignancy was then stratified by: (1) WHO grade (WHO grade 2 vs. WHO grade 3 + 4) and (2) molecular criteria (IDHmut WHO grade 2 + 3 vs. IDHwt glioblastoma + IDHmut astrocytoma WHO grade 4). Age, Pignatti score, SVZ involvement, and T2/FLAIR mismatch sign predicted malignancy only when considering molecular criteria, including IDH mutation and CDKN2A/B deletion status. A multivariate regression confirmed age and T2/FLAIR mismatch sign as independent predictors (p = 0.0009; p = 0.011). A “risk estimation in non-enhancing glioma” (RENEG) score was derived and tested in a validation cohort (2018–2019, n = 40), yielding a higher predictive value than the Pignatti score or the T2/FLAIR mismatch sign (AUC of receiver operating characteristics = 0.89). The prevalence of malignant glioma was high in this series of NEGs, supporting an upfront diagnosis and treatment approach. A clinical score with robust test performance was developed that identifies patients at risk for malignancy.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.